Helius Medical Technologies, Inc. (HSDT)
Chart Events
Performance Outlook
| Previous Close | 8.67 |
| Open | 8.52 |
| Bid | 9.40 x 1300 |
| Ask | 9.85 x 1400 |
| Day's Range | 8.50 - 10.99 |
| 52 Week Range | 5.69 - 20.95 |
| Volume | |
| Avg. Volume | 395,375 |
| Market Cap | 5.337M |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | 0.20 |
| EPS (TTM) | 47.20 |
| Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 128.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HSDT
Related Research
- Helius Medical Technologies, InDaily Spotlight: Dollar Back at HighsThe dollar is up 8% year-to-date and back at cycle highs. The greenback spiked early in the pandemic as global investors flocked to the security of assets denominated in U.S. currency. Indeed, the dollar in 2020 surpassed cycle highs set initially in 2001-2002 and then again in late 2016. But after peaking in April 2020, the greenback declined into 2021. And now in 2022 -- in the wake of the Russian invasion of Ukraine, spiking inflation, and rising global interest rates -- has surpassed cycle highs. Currently, on a real trade-weighted basis, the dollar is 20% above the average valuation over the past 20 years. The fully valued U.S. currency reflects several factors, but primarily the relative strength of the U.S. economy and global investor confidence in the U.S. as the world economy recovers from COVID-19 and battles high prices. We anticipate a trading range around current levels for the greenback for the balance of this year. That's because we think U.S. GDP will start to cool as the Fed has lifted the federal funds rate to tame inflation. What's more, with Treasury prices likely headed lower as the Fed addresses inflation, investors may be selling T-bills and bonds. Lastly, the lofty current valuation of the greenback implies that other currencies -- even gold or other commodities -- are possibly undervalued, and we would expect traders to bid up those values over time.RatingFair ValueEconomic Moatlast yearArgus Research
GlobeNewswireHelius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference
Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month NEWTOWN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will exhibit at the Academy of Neurologic Physical Therapy 2023 Annual Confe
- GlobeNewswire
University of Montreal’s School of Rehabilitation to Purchase Ten PoNS® Devices for Research Study on Stroke Recovery
-- The study will evaluate the optimal time to use PoNS Therapy™ during a patient’s stroke recovery journey --NEWTOWN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has signed an agreement with the School of Rehabilitation at the Université de Montréal (“UdeM”) for the purchase of ten PoNS d
- GlobeNewswire
Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference
-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, clinical data, safety profile -- -- Forum brings together world experts from the core disciplines of clinical neurosciences and rehabilitation -- NEWTOWN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused o
